Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies

Following the clinical success of cancer immunotherapies such as immune checkpoint inhibitors blocking B7/CTLA-4 or PD-1/PD-L1 signaling and ongoing numerous combination therapies in the clinic,3 bispecific antibodies (BsAbs) are now emerging as a growing class of immunotherapies with the potential...

Full description

Bibliographic Details
Main Authors: Gihoon You, Jonghwa Won, Yangsoon Lee, Dain Moon, Yunji Park, Sang Hoon Lee, Seung-Woo Lee
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Vaccines
Subjects:
bispecific antibody
cancer immunotherapy
Online Access:https://www.mdpi.com/2076-393X/9/7/724

Internet

https://www.mdpi.com/2076-393X/9/7/724

Similar Items